Improving the Utility and Translation of Animal Models for Nervous System Disorders Workshop Summary (2013) / Chapter Skim
Currently Skimming:
Appendix B: Workshop Agenda
Appendix B: Workshop Agenda
Pages 83-92
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 83... ...
These statistics translate to drug approval rates that are 50 percent lower than drugs for other therapeutic areas. Given the tremendous disease burden associated with nervous system diseases and disorders, the goal of this workshop is to bring together key stakeholders to discuss potential opportunities for maximizing the translation of effective therapies from animal models to clinical practice.
|
From page 84... ...
DAY ONE 1:30 p.m. Opening Remarks RICHARD HODES, Co-Chair STEVEN PAUL, Co-Chair SESSION I: EVALUATION OF CURRENT ANIMAL MODELS Session Objective: Identify critical limitations impacting translation of therapies from animal models to clinical practice.
|
From page 85... ...
Choice and Validation of Animal Models for CNS Drug Discovery MARK TRICKLEBANK Director and Senior Research Fellow Eli Lilly and Co.
|
From page 86... ...
Cotzias Distinguished Professor of Neurology and Neuroscience Weill Cornell Medical College WALTER KOROSHETZ, Discussant Deputy Director National Institute for Neurological Disorders and Stroke
|
From page 87... ...
APPENDIX B 87 STEVEN PAUL, Discussant Director Helen and Robert Appel Alzheimer's Disease Research Institute Weill Cornell Medical College Breakout 4: Animal Models for Schizophrenia: Cognition Enhancement and Antipsychotic Efficacy HOLLY MOORE, Moderator Associate Professor Clinical Neurobiology in Psychiatry Columbia University MARK GEYER, Discussant Professor Department of Psychiatry University of California, San Diego STEVIN ZORN, Discussant Executive Vice President Neuroscience Research Lundbeck USA Breakout 5: Animal Models for Addiction ATHINA MARKOU, Moderator Professor Department of Psychiatry University of California, San Diego ALAN LESHNER, Discussant Chief Executive Officer American Association for the Advancement of Science GERARD MAREK, Discussant Project Director Neuroscience Development Abbott Laboratories
|
From page 88... ...
ADJOURN DAY TWO Note: Continental breakfast will be available at 8:00 a.m. SESSION III: THE VALUE OF STANDARDIZATION Session Objective: Explore key components of animal model science that would benefit from standardization, such as behavioral paradigms.
|
From page 89... ...
Developing New Methods for Cognitive Translation from Rodent to Human TIM BUSSEY Professor Department of Experimental Psychology University of Cambridge 9:10 a.m. AD Models and the Risk/Benefit Ratio of Standardization LENNART MUCKE Director, Gladstone Institute of Neurological Disease Professor, Department of Neurology University of California, San Francisco 9:25 a.m.
|
From page 90... ...
Choice of Endpoints -- EAE to Approved Drug -- One Huge Success; One Massive Failure LARRY STEINMAN Professor Department of Neurology and Neurological Sciences Stanford University 11:00 a.m. Improving Bidirectional Translation for Nervous System Disorders MICHELA GALLAGHER Krieger-Eisenhower Professor of Psychology and Neuroscience Department of Psychological and Brain Sciences Johns Hopkins University 11:15 a.m.
|
From page 91... ...
DEANNA BARCH Professor of Psychology, Psychiatry and Radiology Washington University GERRY DAWSON Chief Science Officer P1vital HUGO GEERTS Scientific Liaison Officer In Silico Biosciences THOMAS STECKLER Senior Scientific Director Neuroscience Drug Discovery Johnson & Johnson 2:30 p.m. Discussion with Speakers and Participants 3:00 p.m.
|
From page 92... ...
Session Synopsis and Next Steps STEVIN ZORN, Session I Chair RICHARD HODES, Session II Co-Chair STEVEN PAUL, Session II Co-Chair WALTER KOROSHETZ, Session III Chair SHARON ROSENZWEIG-LIPSON, Session IV Chair MARK GEYER, Session V Chair 4:25 p.m. Discussion with Speakers and Participants 5:00 p.m.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.